- Home
- CRBP vs BDTX Comparison
CRBP vs BDTX Comparison
Compare CRBP & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRBP | BDTX |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.8M | 126.5M |
| IPO Year | 2014 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CRBP | BDTX |
|---|---|---|
| Price | $7.63 | $2.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | ★ $50.29 | $10.40 |
| AVG Volume (30 Days) | 138.7K | ★ 604.8K |
| Earning Date | 01-01-0001 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 64.31 | 32.45 |
| EPS | N/A | ★ 0.65 |
| Revenue | ★ $4,822,272.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $220.00 | N/A |
| P/E Ratio | ★ N/A | $3.64 |
| Revenue Growth | ★ 97.62 | N/A |
| 52 Week Low | $4.64 | $1.20 |
| 52 Week High | $20.56 | $4.94 |
Technical Indicators
Market Signals| Indicator | CRBP | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.45 | 53.40 |
| Support Level | $6.73 | $2.42 |
| Resistance Level | $8.43 | $2.86 |
| Average True Range (ATR) | 0.47 | 0.12 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 38.50 | 89.74 |
Price Performance
Historical ComparisonAbout CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.